David Kirske - 14 Mar 2023 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP, Chief Financial Officer
Signature
/s/ David Kirske
Issuer symbol
N/A
Transactions as of
14 Mar 2023
Net transactions value
$0
Form type
4
Filing time
16 Mar 2023, 17:52:37 UTC
Previous filing
03 Jan 2023
Next filing
26 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 14 Mar 2023 Common Stock 200,000 $4.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates.